MARKET

JSPRW

JSPRW

Jasper Therapeutics Inc
NASDAQ
0.0208
-0.0009
-4.15%
Closed 14:06 04/13 EDT
OPEN
0.0187
PREV CLOSE
0.0217
HIGH
0.0208
LOW
0.0187
VOLUME
1.66K
TURNOVER
--
52 WEEK HIGH
0.1475
52 WEEK LOW
0.0152
MARKET CAP
--
P/E (TTM)
-0.0053
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at JSPR last week (0406-0410)?
Weekly Report · 20h ago
Weekly Report: what happened at JSPR last week (0330-0403)?
Weekly Report · 04/06 09:47
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 04/02 21:05
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR), Alto Neuroscience, Inc. (ANRO) and Viridian Therapeutics (VRDN)
TipRanks · 04/02 12:40
Jasper Therapeutics Price Target Cut to $7.00/Share From $12.00 by Evercore ISI Group
Dow Jones · 04/01 17:16
Jasper Therapeutics Is Maintained at Outperform by Evercore ISI Group
Dow Jones · 04/01 17:16
Evercore ISI Group Maintains Outperform on Jasper Therapeutics, Lowers Price Target to $7
Benzinga · 04/01 17:06
Jasper Therapeutics price target lowered to $7 from $12 at Evercore ISI
TipRanks · 04/01 11:59
More
About JSPRW
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS), and stem cell transplant conditioning regimens. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.

Webull offers Jasper Therapeutics Inc stock information, including NASDAQ: JSPRW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JSPRW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JSPRW stock methods without spending real money on the virtual paper trading platform.